type in your search and press enter
BioRestorative Therapies’ Stockholders Approve Institutional Investor Agreement and Exchange Agreements
You May Also Like
Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor
DURHAM, N.C., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an ...
Cancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
Nearly half of the 50+ Immuno-Oncology Clinical Trials that CGI is supporting are combination ...
Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types
Phase 1a/1b trial on track to enroll approximately 280 patientsPhase 1b portion of the ...
